Wellington Management Group LLP Intercept Pharmaceuticals, Inc. Transaction History

Wellington Management Group LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$12.53 - $21.71 $31,224 - $54,101	-2,492 Reduced 2.95%	81,971 $1.1 Million
Q4 2022 Feb 13, 2023	SELL	$11.61 - $16.11 $57,457 - $79,728	-4,949 Reduced 5.54%	84,463 $1.04 Million
Q3 2022 Nov 14, 2022	SELL	$12.21 - $19.7 $60,610 - $97,790	-4,964 Reduced 5.26%	89,412 $1.25 Million
Q1 2022 May 16, 2022	SELL	$13.37 - $17.79 $16,431 - $21,863	-1,229 Reduced 1.29%	94,376 $1.54 Million
Q4 2021 Feb 11, 2022	BUY	$14.28 - $19.53 $1.37 Million - $1.87 Million	95,605 New	95,605 $1.56 Million
Q1 2020 May 14, 2020	SELL	$48.35 - $118.68 $13.2 Million - $32.4 Million	-272,893 Closed	0 $0
Q4 2019 Feb 11, 2020	BUY	$57.36 - $124.1 $15.7 Million - $33.9 Million	272,893 New	272,893 $33.8 Million

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

Stay updated on Wellington Management Group LLP with notifications on news.